Show simple item record

dc.contributor.authorRunge, Hendrik FPen
dc.contributor.authorLacy, Stuarten
dc.contributor.authorBarrans, Sharonen
dc.contributor.authorBeer, Philip Aen
dc.contributor.authorPainter, Danielen
dc.contributor.authorSmith, Alexandraen
dc.contributor.authorRoman, Eveen
dc.contributor.authorBurton, Cathyen
dc.contributor.authorCrouch, Simonen
dc.contributor.authorTooze, Reubenen
dc.contributor.authorHodson, Danielen
dc.date.accessioned2020-09-09T23:31:21Z
dc.date.available2020-09-09T23:31:21Z
dc.date.issued2021-01en
dc.identifier.issn0007-1048
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/310098
dc.description.abstractWe recently published results of targeted sequencing applied to 928 unselected cases of DLBCL registered in the Haematological Malignancy Research Network (HMRN) registry (1). Clustering allowed us to resolve five genomic subtypes. These subtypes shared considerable overlap with those proposed in two independent genomic studies(2, 3), suggesting the potential to use genetics to stratify patients by both risk and biology. In the original studies, clustering techniques were applied to sample cohorts to reveal molecular substructure, but left open the challenge of how to classify an individual patient. This was addressed by the LymphGen classification tool (4). LymphGen assigns an individual case to one of six molecular subtypes. The tool accommodates data from exome or targeted sequencing, either with or without copy number variant (CNV) data. Separate gene expression data allows classification of a seventh, MYC-driven subtype defined by a double hit (DHL) or molecular high-grade (MHG) gene expression signature(5-7).
dc.description.sponsorshipHR was funded by a studentship from the Medical Research Council. DH was supported by a Clinician Scientist Fellowship from the Medical Research Council (MR/M008584/1). The Hodson laboratory receives core funding from Wellcome and MRC to the Wellcome-MRC Cambridge Stem Cell Institute and core funding from the CRUK Cambridge Cancer Centre. HMRN is supported by BCUK 15037 and CRUK 18362.
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.publisherWiley-Blackwell
dc.rightsAll rights reserved
dc.subjectHumansen
dc.subjectCyclophosphamideen
dc.subjectVincristineen
dc.subjectDoxorubicinen
dc.subjectPrednisoneen
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen
dc.subjectPrognosisen
dc.subjectCluster Analysisen
dc.subjectMutationen
dc.subjectLymphoma, Large B-Cell, Diffuseen
dc.subjectTranscriptomeen
dc.subjectRituximaben
dc.subjectProgression-Free Survivalen
dc.titleApplication of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL).en
dc.typeArticle
prism.endingPage220
prism.issueIdentifier1en
prism.publicationDate2021en
prism.publicationNameBritish journal of haematologyen
prism.startingPage216
prism.volume192en
dc.identifier.doi10.17863/CAM.57184
dcterms.dateAccepted2020-09-06en
rioxxterms.versionofrecord10.1111/bjh.17132en
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2021-01en
dc.contributor.orcidRunge, Hendrik FP [0000-0002-4282-1515]
dc.contributor.orcidPainter, Daniel [0000-0002-3936-7569]
dc.contributor.orcidSmith, Alexandra [0000-0002-1111-966X]
dc.contributor.orcidRoman, Eve [0000-0001-7603-3704]
dc.contributor.orcidHodson, Daniel [0000-0001-6225-2033]
dc.identifier.eissn1365-2141
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMedical Research Council (MR/M008584/1)
pubs.funder-project-idMRC (MC_PC_12009)
pubs.funder-project-idMRC (1942725)
pubs.funder-project-idMedical Research Council (MC_PC_17230)
cam.orpheus.successMon Oct 12 07:30:35 BST 2020 - Embargo updated*
cam.orpheus.counter3*
rioxxterms.freetoread.startdate2021-10-03


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record